REGENXBIO Inc. is a clinical-stage biotechnology company developing AAV-based gene therapies using its proprietary NAV Technology Platform, which includes over 100 AAV vectors. The company focuses on retinal, neuromuscular, and neurodegenerative diseases with key pipeline programs including surabgene lomparvovec (wet AMD, diabetic retinopathy, with AbbVie), RGX-202 (Duchenne muscular dystrophy), RGX-121 (MPS II), and RGX-111 (MPS I, with Nippon Shinyaku). It also licenses NAV vectors to third parties including Novartis.
expected 2026-11-24
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-094013 | EDGAR | 108K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038770 | EDGAR | 100K words |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021161 | EDGAR | 96K words |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005085 | EDGAR | 98K words |
| 2022-03-01 | 2021-12-31 | 0001564590-22-008055 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009855 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001564590-20-006826 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004920 | EDGAR | — |
| 2018-03-06 | 2017-12-31 | 0001564590-18-004532 | EDGAR | — |
| 2017-03-07 | 2016-12-31 | 0001564590-17-003576 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336725 | EDGAR | 35K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-268095 | EDGAR | 37K words |
| 2025-08-07 | 2025-06-30 | 0001193125-25-174953 | EDGAR | 36K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069237 | EDGAR | 31K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122330 | EDGAR | 27K words |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089320 | EDGAR | 27K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055691 | EDGAR | 25K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061144 | EDGAR | 28K words |
| 2023-08-02 | 2023-06-30 | 0000950170-23-037178 | EDGAR | 26K words |
| 2023-05-03 | 2023-03-31 | 0000950170-23-017200 | EDGAR | 23K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021567 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001564590-22-027764 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-23 | 0001193125-26-399377 | EDGAR | 1K words |
| 2026-08-25 | 0001193125-26-365287 | EDGAR | 1K words |
| 2026-08-24 | 0001193125-26-363786 | EDGAR | 1K words |
| 2026-08-06 | 0001193125-26-336716 | EDGAR | 4K words |
| 2026-07-20 | 0001193125-26-308342 | EDGAR | 1K words |
| 2026-03-20 | 0001193125-26-117913 | EDGAR | 1K words |
| 2026-03-05 | 0001193125-26-092566 | EDGAR | 4K words |
| 2026-02-10 | 0001193125-26-043342 | EDGAR | 2K words |
| 2026-01-28 | 0001193125-26-026139 | EDGAR | 2K words |
| 2025-11-06 | 0001193125-25-268101 | EDGAR | 3K words |
188 total filings indexed. 156 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001590877 |
| Ticker | RGNX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.regenxbio.com |
| Listed | 2015-09-17 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RGNX (~200 tokens, structured JSON with cryptographic provenance)